SARS-CoV-2 Nucleocapsid antibody

Catalog No. ABIN6952435

This anti-SARS-CoV-2 Nucleocapsid antibody is a Mouse Monoclonal antibody detecting SARS-CoV-2 Nucleocapsid in ELISA and WB. Suitable for SARS Coronavirus-2 (SARS-CoV-2) and Virus. This Primary Antibody has been cited in 6+ publications.

Quick Overview for SARS-CoV-2 Nucleocapsid antibody (ABIN6952435)

Target: SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)

Reactivity: SARS Coronavirus-2 (SARS-CoV-2), Virus

Host: Mouse

Clonality: Monoclonal

Conjugate: This SARS-CoV-2 Nucleocapsid antibody is un-conjugated

Application: ELISA, Western Blotting (WB)

Clone: 1C7

Product Details anti-SARS-CoV-2 Nucleocapsid Antibody

Purification: Purified by Protein G.

Immunogen: Recombinant SARS-CoV-2 N protein (His-tag)

Isotype: IgG2b

Application Details

Application Notes: WB 1:300-1000
ELISA 1:500-1000

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M PBS( pH 7.4) with 0.1 % Proclin300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20 °C

Expiry Date: 12 months

References for anti-SARS-CoV-2 Nucleocapsid antibody (ABIN6952435)

Sperber, Sutter, Müller, Müller, Schwarzer: "The Bovine Seminal Plasma Protein PDC-109 Possesses Pan-Antiviral Activity." in: Viruses, Vol. 14, Issue 9, (2022) (PubMed).

Le-Trilling, Mennerich, Schuler, Sakson, Lill, Kasarla, Kopczynski, Loroch, Flores-Martinez, Katschinski, Wohlgemuth, Gunzer, Meyer, Phapale, Dittmer, Sickmann, Trilling: "Identification of herbal teas and their compounds eliciting antiviral activity against SARS-CoV-2 in vitro." in: BMC biology, Vol. 20, Issue 1, pp. 264, (2022) (PubMed).

Wenzek, Steinbach, Wirsdörfer, Sutter, Boehme, Geffers, Klopfleisch, Bruder, Jendrossek, Buer, Westendorf, Knuschke: "CD47 restricts antiviral function of alveolar macrophages during influenza virus infection." in: iScience, Vol. 25, Issue 12, pp. 105540, (2022) (PubMed).

Krempe, Schöler, Katschinski, Herrmann, Anastasiou, Elsner, Ross, Scholz, Dittmer, Miethe, Le-Trilling, Trilling: "A rapid test recognizing mucosal SARS-CoV-2-specific antibodies distinguishes prodromal from convalescent COVID-19." in: iScience, Vol. 24, Issue 10, pp. 103194, (2021) (PubMed).

Schöler, Le-Trilling, Eilbrecht, Mennerich, Anastasiou, Krawczyk, Herrmann, Dittmer, Trilling: "A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds." in: Frontiers in immunology, Vol. 11, pp. 573526, (2020) (PubMed).

Chen, Juric, Cosgrove, Bowman, Fitzpatrick, Schoech, Clark, Coop: "Allele frequency dynamics in a pedigreed natural population." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, Issue 6, pp. 2158-2164, (2019) (PubMed).

Target Details for SARS-CoV-2 Nucleocapsid

Target: SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)

Alternative Name: SARS-CoV-2 N protein

Target Type: Viral Protein

UniProt: P0DTC9